Evidence map›Paper›PMID 33788895›Full record

ArticlePLoS pathogens2021

TcpC inhibits toll-like receptor signaling pathway by serving as an E3 ubiquitin ligase that promotes degradation of myeloid differentiation factor 88.

Jia-Qi Fang, Qian Ou, Jun Pan, Jie Fang, Da-Yong Zhang, Miao-Qi Qiu, Yue-Qi Li, Xiao-Hui Wang, Xue-Yu Yang, Zhe Chi and 4 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. HypervirulentMicrobiology spectrum · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Uropathogen and host responses in pyelonephritis.Nature reviews. Nephrology · 2023
    Review
  8. Article
  9. The Promoter of the Immune-Modulating GeneInternational journal of molecular sciences · 2022
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Jia-Qi FangInstitute of Translational Medicine, Zhejiang University City College, Hangzhou, Peoples Republic of China.
Qian OuInstitute of Translational Medicine, Zhejiang University City College, Hangzhou, Peoples Republic of China.
Jun PanCancer Institute, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Peoples Republic of China.ORCID 0000-0002-4031-5766
Jie FangInstitute of Translational Medicine, Zhejiang University City College, Hangzhou, Peoples Republic of China.ORCID 0000-0003-2881-4033
Da-Yong ZhangInstitute of Translational Medicine, Zhejiang University City College, Hangzhou, Peoples Republic of China.
Miao-Qi QiuDepartment of Clinical Medicine, Zhejiang University City College School of Medicine, Hangzhou, Peoples Republic of China.
Yue-Qi LiDepartment of Clinical Medicine, Zhejiang University City College School of Medicine, Hangzhou, Peoples Republic of China.
Xiao-Hui WangDepartment of Clinical Medicine, Zhejiang University City College School of Medicine, Hangzhou, Peoples Republic of China.
Xue-Yu YangDepartment of Clinical Medicine, Zhejiang University City College School of Medicine, Hangzhou, Peoples Republic of China.
Zhe ChiInstitute of Translational Medicine, Zhejiang University City College, Hangzhou, Peoples Republic of China.ORCID 0000-0001-5234-2086
Wei GaoInstitute of Translational Medicine, Zhejiang University City College, Hangzhou, Peoples Republic of China.
Jun-Ping GuoInstitute of Translational Medicine, Zhejiang University City College, Hangzhou, Peoples Republic of China.ORCID 0000-0002-3343-4564
Thomas MiethkeInstitute of Medical Microbiology and Hygiene, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany.ORCID 0000-0001-7451-5857
Jian-Ping PanInstitute of Translational Medicine, Zhejiang University City College, Hangzhou, Peoples Republic of China.
Zhejiang University · CNSecond Affiliated Hospital of Zhejiang University · CNHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TcpC is a virulence factor of uropathogenic E. coli (UPEC). It was found that TIR domain of TcpC impedes TLR signaling by direct association with MyD88. It has been a long-standing question whether bacterial pathogens have evolved a mechanism to manipulate MyD88 degradation by ubiquitin-proteasome pathway. Here, we show that TcpC is a MyD88-targeted E3 ubiquitin ligase. Kidney macrophages from mice with pyelonephritis induced by TcpC-secreting UPEC showed significantly decreased MyD88 protein levels. Recombinant TcpC (rTcpC) dose-dependently inhibited protein but not mRNA levels of MyD88 in macrophages. Moreover, rTcpC significantly promoted MyD88 ubiquitination and accumulation in proteasomes in macrophages. Cys12 and Trp106 in TcpC are crucial amino acids in maintaining its E3 activity. Therefore, TcpC blocks TLR signaling pathway by degradation of MyD88 through ubiquitin-proteasome system. Our findings provide not only a novel biochemical mechanism underlying TcpC-medicated immune evasion, but also the first example that bacterial pathogens inhibit MyD88-mediated signaling pathway by virulence factors that function as E3 ubiquitin ligase.

Indexed as

AnimalsCell LineEscherichia coli ProteinsFemaleHumansImmune EvasionMacrophagesMiceMice, Inbred C57BLMyeloid Differentiation Factor 88PyelonephritisSignal TransductionToll-Like ReceptorsUbiquitin-Protein LigasesUropathogenic Escherichia coliVirulenceEscherichia coli ProteinsMyeloid Differentiation Factor 88TcpC protein, E coliToll-Like ReceptorsUbiquitin-Protein LigasesVirulence Factors

Identifiers

PMID33788895
PMCPMC8041205
OpenAlexW3146236150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.